Table 2 Distribution of knowledge section

1. Infection outside the hospital with no symptoms, but the onset in the hospital during the incubation period is also a community-acquired pneumonia.

371(58.24)

2. The probability of community-acquired pneumonia in immunodeficiency patients is the same as that of healthy controls.

339(53.22)

3. Chest pain or chest discomfort is also the common clinical manifestation of community-acquired pneumonia.

376(59.03)

4. The SARS-CoV-2 is contagious during the incubation period.

569(89.32)

5. Healthy individuals can avoid infection from SARS-CoV-2-contaminated objects as long as they hold their breath.

549(86.19)

6. The COVID-19 mainly damages the lungs and has little impact on other organs.

500(78.49)

7. The main clinical manifestations of COVID-19 are fever, dry cough, fatigue, and some patients will suffer from nasal congestion, runny nose, sore throat, loss of smell/taste, muscle pain, diarrhea, etc.

591(92.78)

8. Most children have relatively mild symptoms after being infected with SARS-CoV-2, and some only show digestive tract reactions such as vomiting and diarrhea.

450(70.64)

9. In the case of ineffective community empiric treatment, the identification of community-acquired pneumonia pathogens can be realized by X-ray.

453(71.11)

10. The nucleic acid detection of COVID-19 was based on polymerase chain reaction.

333(52.28)

11. Empiric treatment of community-acquired pneumonia included traditional Chinese medicine such as Lianhua Qingwen capsules.

262(41.13)

12. If patients with COVID-19 have gastrointestinal discomfort during the observation period, these patients can try to use Huo Xiang Zhengqi capsules of TCM therapy.

361(56.67)